Molecular Insight Expands Executive Research and Development Team
Posted on: Thursday, 18 August 2005, 09:00 CDT
Molecular Insight Pharmaceuticals, Inc. today announced the appointment of John A. Barrett, Ph.D., as Vice President of Research, and the promotion of James F. Kronauge, Ph.D., to Vice President of Process Chemistry. Dr. Barrett brings over 20 years of research and development experience in cardiology, imaging and oncology from previous positions with Johnson & Johnson, DuPont Merck, EPIX Pharmaceuticals and, most recently, Infinity Pharmaceuticals. Dr. Kronauge, a key member of Molecular Insight's research team since 1999, most recently as Director of Pre-clinical Development, has over 25 years experience in the development of cardiovascular imaging products. Drs. Barrett and Kronauge will report to John Babich, Ph.D., President and Chief Scientific Officer of Molecular Insight.
"John and Jim are outstanding scientists whose knowledge and industry experience will provide immediate value to our research team as we expand and scale up our clinical pipeline," said Dr. Babich. "John's appointment and Jim's expanded responsibilities reflect our commitment to enhancing our research and development capabilities so that we can continue to advance molecular medicine candidates in the areas of cardiovascular disease, cancer and neurology from our Ultratrace(TM) and SAAC(TM) technology platforms," he added.
Molecular Insight's development pipeline includes BMIPP (iodofiltic acid I123), a molecular imaging pharmaceutical for the detection of cardiac ischemia, and Ultratrace(TM) MIBG (MIP-120T) for the treatment of neuroendocrine tumors. BMIPP recently completed Phase 2b development for use in triaging emergency room patients with suspected acute coronary syndrome. Ultratrace(TM) MIBG is in late preclinical development for the visualization and treatment of neuroendocrine tumors. The company has additional compounds in preclinical development.
Dr. Barrett's career encompasses more than 20 years of work in the discovery and development of agents in oncology and angiogenesis-directed tumor imaging and therapy. He is the inventor or co-inventor on eight issued cardiology and imaging patents. He joined Molecular Insight from Infinity Pharmaceuticals, where he was Senior Director Pharmacology/Toxicology, ADME and Bioanalytical. Prior to Infinity, Dr. Barrett served at EPIX Pharmaceuticals as Senior Director of Pharmacology/Toxicology. Previously, he held research and research management positions of increasing responsibility at a number of pharmaceutical companies, including DuPont Merck Pharmaceuticals, where he was most recently Director, Discovery Biology Research Imaging; Johnson & Johnson's RWJ Research Institute; and Rorer Pharmaceuticals. Dr. Barrett received his Ph.D. in Pharmaceutical Sciences from St. John's University.
Dr. Kronauge has been an active researcher in the field of radiology and nuclear medicine for the past 20 years and has published more than 50 research articles in a variety of peer-reviewed journals. He is inventor or co-inventor of six issued patents, including one for the use of Cardiolite(R), the world's leading perfusion imaging agent for the detection of cardiac ischemia. He was closely involved with the discovery and development of CardioGen(R) (Bracco) and Mebrofennin(R) (Bracco). Prior to joining Molecular Insight, Dr. Kronauge was Assistant Professor of Radiology at Harvard Medical School and Associate Director of the Radiopharmacy in the Joint Program in Nuclear Medicine at Brigham and Women's Hospital, Boston, Mass. Dr. Kronauge received his Ph.D. in Inorganic Chemistry from M.I.T.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals is focused on becoming a leader in the rapidly emerging field of molecular medicine through the development and commercialization of innovative pharmaceuticals that utilize highly specific targeting technologies designed to meaningfully improve patient diagnosis, treatment and management. The company is leveraging synergies in functional molecular imaging and targeted radiotherapeutics to create a new model for integrated healthcare. Molecular Insight's lead product candidate, BMIPP (iodofiltic acid I123), has completed Phase 2b clinical development for use in triaging emergency room patients with suspected acute coronary syndrome, a situation that results in over six million emergency room visits annually in the United States. The company's first radiotherapeutic candidate, Ultratrace(TM) MIBG (MIP-120T), for the evaluation and treatment of neuroendocrine tumors, is in late preclinical development. Molecular Insight's pipeline leverages proprietary technologies for targeting, visualizing, treating, and monitoring disease in cardiology, oncology and neurology. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts; its Web site address is: www.molecularinsight.com.
Source: Business Wire
Related Articles
- Optical Networking Equipment Sales to Top $120 Billion Over Five Years, Says Insight Research Corp.
- Healthcare Industry Spending on Telecommunications Services Hits $55 Billion Over Next Five Years, Says Insight Research
- IPTV, Streaming Movie and Music Industry Will Generate $70 Billion Over Six Years, Says Insight Research
- Residential Phone Customers' Move to Cable Calling Means Phone Companies Lose $8 Billion Over Five Years, Says Insight Research Corp.
- Consumers Adopting Dual Mode Phones for Fixed Mobile Convergence While Enterprises Lag Behind, Says Insight Research Corporation
- Carrier Ethernet Market Expected to Reach $1.4 Billion Says Insight Research
- Timothy R. Wright Appointed President of Tyco Healthcare's Pharmaceutical Products and Imaging Solutions Units
- Public Ethernet Services Poised for Growth Spurt in 2007, Says Insight Research
- Who helped make John Wayne great? Director John Ford
- As Enterprise Network Complexity Rises, Outsourcing to a Managed Service Provider Increases Savings, Says Insight Research
 |
 |
User Comments (0)
RSS Feeds